C12N 2795/18163
By chemical treatment
Official title: by chemical treatment
C12N2795/18163 (By chemical treatment) appears on 6 US grants and 1 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 1
- Assignees
- 3
- Inventors
- 4
- Latest grant
- 25 Jun 2002
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Treating blood or blood products with compounds which have a mustard, azirdinium or aziridine group and a nucleic acid binding group25 Jun 2002US 6,410,219 B1Cerus Corporation
- Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety9 Jan 2001US 6,171,777 B2Cerus Corporation
- Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety7 Nov 2000US 6,143,490 ACerus Corporation
- Methods and compositions for the selective modification of viral nucleic acids5 Sep 2000US 6,114,108 AV. I. Technologies, Inc.
- Method for inactivating pathogens in red cell compositions using quinacrine mustard25 Nov 1997US 5,691,132 ACerus Corporation
Most cited
By later US patents
- Method for inactivating pathogens in red cell compositions using quinacrine mustard63US 5,691,132 ACerus Corporation · 1997
- Treating red blood cell solutions with anti-viral agents57US 5,559,250 ASteritech, Inc. · 1996
- Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety47US 6,171,777 B2Cerus Corporation · 2001
- Treating blood or blood products with compounds which have a mustard, azirdinium or aziridine group and a nucleic acid binding group36US 6,410,219 B1Cerus Corporation · 2002
- Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety35US 6,143,490 ACerus Corporation · 2000